EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies

Timothy S Dutill, Michelle C Archer, Joseph McCollum, Chris Press, Lisa McNeill, Linda Hawkins, Tony Phan, Erik Laursen, Richard Cabullos, Lisa Bouchard, Regie J Castro, Mong-Wu Lin und 9 weitere

Frontiers in Drug Delivery · 2022

DOI: 10.3389/fddev.2022.1043756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Drug Delivery, 2022. Verfasst von Timothy S Dutill und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lyophilization Technology, Inc, Warminster, PA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Promising clinical efficacy results have generated considerable enthusiasm for the potential impact of adjuvant-containing subunit tuberculosis vaccines. The development of a thermostable tuberculosis vaccine formulation could have significant benefits on both the cost and feasibility of global vaccine distribution. The tuberculosis vaccine candidate ID93 + GLA-SE has reached Phase 2 clinical testing, demonstrating safety and immunogenicity as a two-vial point-of-care mixture. Earlier publications have detailed efforts to develop a lead candidate single-vial lyophilized thermostable ID93 + GLA-SE vaccine formulation. The present report describes the lyophilization process development and scale-up of the lead candidate thermostable ID93 + GLA-SE composition. The manufacture of three full-scale engineering batches was followed by one batch made and released under current Good Manufacturing Practices (cGMP). Up to 4.5 years of stability data were collected. The cGMP lyophilized ID93 + GLA-SE passed all manufacturing release test criteria and maintained stability for at least 3 months when stored at 37°C and up to 24 months when stored at 5°C. This work represents the first advancement of a thermostable adjuvant-containing subunit tuberculosis vaccine to clinical testing readiness.

Schlagwörter

Stichwörter der Autor:innen

GLA-SEID93adjuvant-containing vaccinecGMPlyophilizationrecombinant subunit antigenthermostabletuberculosis vaccine

Autor:innen und Institutionen

  • Lyophilization Technology, Inc, Warminster, PA, USA.
  • Access to Advanced Health Institute (AAHI; formerly Infectious Disease Research Institute), Seattle, WA, USA.
  • Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria.
  • Department of Global Health, University of Washington, Seattle, WA, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Dutill, T. S., Archer, M. C., McCollum, J., Press, C., McNeill, L., Hawkins, L., Phan, T., Laursen, E., Cabullos, R., Bouchard, L., Castro, R. J., Lin, M. W., Roco, J., Blois, C., Adeagbo, B., Guderian, J. A., Gerhardt, A., Beckmann, A. M., Trappler, E. H., …, & Fox, C. B. (2022). Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies. Frontiers in Drug Delivery. https://doi.org/10.3389/fddev.2022.1043756

Vancouver

Dutill TS, Archer MC, McCollum J, Press C, McNeill L, Hawkins L, et al. Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies. Frontiers in Drug Delivery. 2022. doi:10.3389/fddev.2022.1043756

BibTeX
@article{Dutill2022,
  author = {Dutill, Timothy S and Archer, Michelle C and McCollum, Joseph and Press, Chris and McNeill, Lisa and Hawkins, Linda and Phan, Tony and Laursen, Erik and Cabullos, Richard and Bouchard, Lisa and Castro, Regie J and Lin, Mong-Wu and Roco, Jeralyn and Blois, Cecile and Adeagbo, Babatunde and Guderian, Jeffrey A and Gerhardt, Alana and Beckmann, Anna Marie and Trappler, Edward H and Kramer, Ryan M and Fox, Christopher B},
  title = {Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies},
  journal = {Frontiers in Drug Delivery},
  year = {2022},
  doi = {10.3389/fddev.2022.1043756}
}
Kostenlos starten →